Avantor, Inc. AVTR
At Avantor, everything we do is tied to our unique mission of setting science in motion to create a better world.
We are a leading global provider of mission-critical products and services to customers in the biopharma & healthcare, education & government, and advanced technologies & applied materials end markets. Our business model is grounded in supporting our customers from discovery to delivery and Avantor is embedded in virtually every stage of the most important research, scale-up and manufacturing activities in the industries we serve.
We work with customers across these sophisticated, science-driven industries that require innovation and adherence to the most demanding technical and regulatory requirements. Our customer-centric innovation model enables us to provide solutions for some of the most demanding applications, and we leverage our comprehensive offering and access to early-stage research to identify and develop content and solutions that ultimately become specified into our customers' approved production platforms.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.55B | $6.78B | $6.97B | $7.51B | $7.39B | $6.39B | $6.04B | $5.86B | $1.25B | — |
| Cost of revenue | $4.41B | $4.50B | $4.60B | $4.91B | $4.88B | $4.31B | $4.12B | $4.04B | $814.6M | — |
| Gross profit | $2.14B | $2.28B | $2.36B | $2.60B | $2.50B | $2.08B | $1.92B | $1.82B | $432.8M | — |
| SG&A | $1.60B | $1.64B | $1.51B | $1.47B | $1.53B | $1.37B | $1.37B | $1.41B | $449.7M | — |
| Operating income | -$246.2M | $1.08B | $696.4M | $1.13B | $972.2M | $706.8M | $551.8M | $413.5M | -$210.4M | — |
| Interest expense | $169.8M | $218.8M | $284.8M | $265.8M | $217.4M | $307.6M | $440.0M | $523.8M | $200.9M | — |
| Pre-tax income | -$441.3M | $853.9M | $410.5M | $851.1M | $753.0M | $62.3M | $40.6M | -$113.8M | -$460.2M | — |
| Income tax | $88.9M | $142.4M | $89.4M | $164.6M | $180.4M | $54.3M | $2.8M | $26.9M | $314.9M | — |
| Net income | -$530.2M | $711.5M | $321.1M | $686.5M | $572.6M | $116.6M | $37.8M | -$86.9M | -$112.7M | — |
| EPS, basic | -0.78 | 1.05 | 0.48 | 1.02 | 0.86 | 0.09 | -0.84 | -2.69 | — | — |
| EPS, diluted | -0.78 | 1.04 | 0.47 | 1.01 | 0.85 | 0.09 | -0.84 | -2.69 | -2.75 | — |
| Shares, diluted (wtd. avg.) | $680.6M | $681.9M | $678.4M | $679.4M | $599.6M | $583.4M | $401.2M | $132.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $365.4M | $261.9M | $287.7M | $396.9M | $327.1M | $289.2M | $189.3M | $187.7M | $188.5M | $66.0M |
| Receivables | $1.07B | $1.03B | $1.15B | $1.22B | $1.22B | $1.11B | $988.8M | $931.2M | — | — |
| Inventory | $818.2M | $731.5M | $828.1M | $913.5M | $872.0M | $739.6M | $711.2M | $671.1M | — | — |
| Total current assets | $2.45B | $2.15B | $2.38B | $2.66B | $2.48B | $2.23B | $2.02B | $1.90B | — | — |
| Property, plant and equipment | $766.8M | $708.1M | $737.5M | $727.0M | $705.5M | $549.9M | $557.0M | $598.6M | — | — |
| Goodwill | $4.99B | $5.54B | $5.72B | $5.65B | $5.34B | $2.86B | $2.77B | $2.78B | $2.85B | — |
| Other intangibles | $3.10B | $3.27B | $3.68B | $4.04B | $5.05B | $3.96B | $4.13B | $4.47B | — | — |
| Total assets | $11.79B | $12.11B | $12.97B | $13.46B | $13.90B | $9.91B | $9.77B | $9.91B | — | — |
| Accounts payable | $741.7M | $662.8M | $625.9M | $758.2M | $755.1M | $678.9M | $560.2M | $557.4M | — | — |
| Short-term debt | $30.8M | $821.1M | $259.9M | $364.2M | $45.2M | $26.4M | $93.5M | $142.4M | — | — |
| Total current liabilities | $1.38B | $2.01B | $1.48B | $1.66B | $1.45B | $1.24B | $1.07B | $1.10B | — | — |
| Long-term debt | $3.92B | $3.23B | $5.28B | $5.92B | $6.98B | $4.87B | $5.02B | $6.78B | — | — |
| Total liabilities | $6.23B | $6.16B | $7.72B | $8.61B | $9.70B | $7.23B | $7.31B | $9.10B | — | — |
| Retained earnings | $1.67B | $2.20B | $1.49B | $1.17B | $483.9M | -$88.7M | -$203.7M | -$238.4M | — | — |
| Total equity | $5.57B | $5.96B | $5.25B | $4.86B | $4.20B | $2.67B | $2.46B | -$3.05B | -$2.62B | -$510.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $623.8M | $840.8M | $870.0M | $843.6M | $953.6M | $929.8M | $354.0M | $200.5M | -$167.5M | — |
| Depreciation and amortisation | $109.1M | $105.7M | $94.6M | $87.2M | $88.4M | $87.9M | $86.6M | $83.3M | $34.0M | — |
| Stock-based compensation | $46.4M | $46.8M | $40.5M | $45.8M | $50.7M | $44.1M | $67.9M | $18.4M | $48.2M | — |
| Capital expenditure | $128.8M | $148.8M | $146.4M | $133.4M | $111.1M | $61.6M | $51.6M | $37.7M | $25.2M | — |
| Investing cash flow | -$130.5M | $438.9M | -$143.7M | -$109.6M | -$4.12B | -$59.1M | -$42.1M | -$23.2M | -$6.68B | — |
| Financing cash flow | -$409.4M | -$1.28B | -$843.7M | -$648.7M | $3.22B | -$782.9M | -$307.8M | -$170.3M | $6.96B | — |
| Buybacks | $75.1M | $0 | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-007118.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |
| TXG | 10x Genomics, Inc. | $8.14B | — | 5.2% |